The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,509,566 | -1,326,166 |
| Depreciation expense | 5,991 | 11,520 |
| Net change in unrealized depreciation on investment in gold bullion | 30,968 | -107,477 |
| Gain on sale of gold bullions | 98,427 | 62,469 |
| Stock issued for services | 834,600 | - |
| Impairment of right of use asset | - | 0 |
| Imputed interest - related party | 20,379 | 40,093 |
| Fair value of options issued for services | 4,197 | 8,394 |
| Warrants issued/(cancelled) to consultants | -97,842 | -98,069 |
| Decrease prepaid expenses | -1,467 | -13,508 |
| (increase) in inventory | 22,183 | - |
| Decrease in operating lease right-of-use, net | -14,434 | -27,662 |
| Increase in accrued expenses and other payables - related party | 207,487 | 413,426 |
| Decrease in accounts payable | -34,264 | 34,514 |
| Decrease in operating lease liabilities, current | -14,784 | -28,698 |
| Net cash used in operating activities | -461,859 | -877,624 |
| Proceeds from sale of investment in gold | 222,754 | 147,238 |
| Purchase of fixed assets | 0 | 3,783 |
| Net cash provided by investing activities | 222,754 | 143,455 |
| Proceeds from standby equity purchase agreement | 1,069,335 | 856,367 |
| Payment of debt offering costs | 0 | 10,000 |
| Principal payments on debt - related party | 50,000 | 0 |
| Net cash provided by financing activities | 1,019,335 | 846,367 |
| Net change in cash and cash equivalents | 780,230 | 112,198 |
| Cash and cash equivalents at beginning of period | 673,264 | - |
| Cash and cash equivalents at end of period | 1,565,692 | - |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)